|
KMID : 0366219850200020221
|
|
Korean Journal of Hematology
1985 Volume.20 No. 2 p.221 ~ p.228
|
|
|
N4-behenoyl-l-beta-D-arabinofuranosylcytosine(BH-AC), its Clinical use in Acute Leukemia
|
|
홍영선/Y S Hong
진종률/양기정/홍대식/김용수/민우성/김춘추/김동집/J Y Jin/K J Yang/D S Hong/Y S Kim/W S Min/C C Kim/D J Kim
|
|
|
Abstract
|
|
|
Cytosine arabinoside(ars-C) has been a backbone of current antileukemic therapy,
which requires a very precise dosage schedule to obtain full therapeutic effects as a
consequence of its S-phase specificity and rapid degradation by cytidine deaminase.
BH-AC, one of N4acyl derivatives from ara-C with long chain fatty acid
in the acyl group, possesses a pronounced antileukemic effect regardless of the
treatment schedule, and is chemically resistant to cytidine deaminase.
The authors experienced complete remission in one case of acute myelocytic leukemia
and in one case of acute Iymphocytic leukemia, with the administration of BH-AC,
combined with several other chemotherapeutic agents, without significant side effects.
So, we would like to introduce our therapeutic protocols with brief review of
literatures in this field.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|